Nxstage Medical Price Target Increased to $18.00 by Analysts at Canaccord Genuity (NXTM)
A number of other firms have also recently commented on NXTM. Analysts at Piper Jaffray cut their price target on shares of Nxstage Medical from $18.00 to $16.00 in a research note to investors on Friday, March 1st. They now have an “overweight” rating on the stock. Separately, analysts at Feltl & Co. cut their price target on shares of Nxstage Medical from $13.00 to $11.50 in a research note to investors on Friday, March 1st. They now have a “hold” rating on the stock. Finally, analysts at Zacks downgraded shares of Nxstage Medical from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, February 14th. They now have a $14.00 price target on the stock.
Seven research analysts have rated the stock with a buy rating, two have given an overweight rating, and three have given a hold rating to the company’s stock. Nxstage Medical has an average rating of “overweight” and an average price target of $15.28.
Shares of Nxstage Medical traded down 0.73% during mid-day trading on Monday, hitting $10.92. Nxstage Medical has a 52 week low of $10.15 and a 52 week high of $19.94. The stock’s 50-day moving average is currently $11.45. The company’s market cap is $648.1 million.
Nxstage Medical last released its earnings data on Thursday, February 28th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.01. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $63.54 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 14.0% on a year-over-year basis. Nxstage Medical has set its Q1 guidance at ($0.09)-(0.08) EPS and its FY13 guidance at ($0.28)-(0.22) EPS. On average, analysts predict that Nxstage Medical will post $-0.22 earnings per share for the current fiscal year.
NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.